Drug pseudoallergy

Summary

Drug pseudoallergy (MONDO:0044982) is a disease and 13 clinical trials. Top therapeutic interventions include cefaclor anhydrous, cephalexin anhydrous, and cefuroxime. A subtype of pseudoallergy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	drug pseudoallergy
Mondo ID	MONDO:0044982
SNOMED CT	609398007
UMLS	C3662272
MedGen	783426
Is cancer (heuristic)	no

Also known as: drug allergy · drug pseudoallergy

Disease family

This is a subtype of pseudoallergy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › hypersensitivity reaction disease › pseudoallergy › drug pseudoallergy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06414694	PHASE4	ENROLLING_BY_INVITATION	Inpatient Penicillin Delabeling for Low-Risk Patients
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT02118987	PHASE1	COMPLETED	Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
NCT05820802	Not specified	RECRUITING	High Dimensional Analysis of Immune Cells in Pediatric Patients
NCT06803758	Not specified	RECRUITING	Teicoplanin Allergy Testing Using Autologous Serum (TATAS)
NCT07011212	Not specified	NOT_YET_RECRUITING	In Search of the Correct Diagnosis of Beta-lactam Allergy: From the Validation of a Risk Stratification Tool to Accurate Endotyping
NCT07127835	Not specified	RECRUITING	Provocation After Nurse-Directed Assessment (PANDA) Study
NCT02094638	Not specified	COMPLETED	Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
NCT03164044	Not specified	UNKNOWN	Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
NCT03784482	Not specified	COMPLETED	Multiple Drug Hypersensitivity Syndrome
NCT04920721	Not specified	UNKNOWN	Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy
NCT05706246	Not specified	COMPLETED	Perioperative Hypersensitivity in Children
NCT06399601	Not specified	UNKNOWN	A Training Program of Drug Allergy for Healthcare Professionals

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEFACLOR ANHYDROUS	4	3
CEPHALEXIN ANHYDROUS	4	3
CEFUROXIME	4	2
CEFADROXIL	4	1
CEFDINIR	4	1
CEFEPIME	4	1
CEFIXIME	4	1
CEFPODOXIME	4	1
CEFPODOXIME PROXETIL	4	1
CEFTAZIDIME	4	1
CEFTRIAXONE	4	1
CHEMBL1555813	0	1
CHEMBL388266	0	1
CHEMBL4740200	0	1